MMI is proud to have partnered with Moximed on an FDA-regulated IDE study to investigate the safety and effectiveness of the MISHA Knee System as a treatment option for younger patients with mild to moderate OA.
The FDA granted RMAT designation to DiscGenics’ Injectable Disc Cell Therapy for degenerative disc disease.
A newly signed law permits the FDA to clear a drug for human clinical trials while bypassing animal trials.
Ongoing consolidations and investment has prompted strong growth in new technologies for treatment of extremities, including the foot and ankle.
Medtronic has just announced its first FDA approval for an MRI-friendly internal defibrillator.
While IBM’s Watson entering the field of medical imaging analysis is exciting news, it will still be some time before imaging analysis software sees routine clinical use.
A recent study shows that the high up-front cost of robotic cardiac surgical solutions is offset by lower post-surgery costs.
Dr. Steven Falowski broke new ground by livestreaming the implantation of neurostimulators to Medtronic engineers.
A medical device reimbursement strategy expert recently shared some of his top tips for successful clinical trial design.
With the launch of the National Medical Device Postmarket Surveillance System still years away, manufacturers should focus on the quality of their clinical trial data to increase adoption.
A new guidance document, “Patient Preference Information –Submission, Review in PMAs, HDE Applications, and De Novo Requests, and Inclusion in Device Labeling,” aims to allow patient perspectives to play a greater role in the regulatory process.
For the first time the orthopedic stem cell market was the fastest growing orthopedic biomaterial segment.
